A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
NCT ID: NCT03334396
Last Updated: 2020-08-18
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
660 participants
INTERVENTIONAL
2017-11-23
2019-08-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis
NCT03334422
A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03435081
A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis
NCT03334435
A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable
NCT03428100
A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis
NCT03952559
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
4 milligram (mg) Baricitinib
4 mg Baricitinib administered orally once daily. Placebo 1 mg and 2 mg administered orally every day to match.
Baricitinib
Administered orally.
Placebo
Administered orally.
2 mg Baricitinib
2 mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
Baricitinib
Administered orally.
Placebo
Administered orally.
1 mg Baricitinib
1 mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
Baricitinib
Administered orally.
Placebo
Administered orally.
Placebo
Placebo administered orally once daily.
Placebo
Administered orally.
4 mg Baricitinib Maximum Extended Enrollment Cohort
4 mg Baricitinib administered orally once daily. Placebo 1 mg, and 2 mg administered orally every day to match.
Baricitinib
Administered orally.
Placebo
Administered orally.
2 mg Baricitinib Maximum Extended Enrollment Cohort
2 mg Baricitinib administered orally once daily. Placebo 1 mg and 4 mg administered orally every day to match.
Baricitinib
Administered orally.
Placebo
Administered orally.
1 mg Baricitinib Maximum Extended Enrollment Cohort
1 mg Baricitinib administered orally once daily. Placebo 2 mg and 4 mg administered orally every day to match.
Baricitinib
Administered orally.
Placebo
Administered orally.
Placebo Maximum Extended Enrollment Cohort
Placebo administered orally once daily.
Placebo
Administered orally.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Baricitinib
Administered orally.
Placebo
Administered orally.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have had inadequate response or intolerance to existing topical (applied to the skin) medications within 6 months preceding screening.
* Are willing to discontinue certain treatments for eczema (such as systemic and topical treatments during a washout period).
* Agree to use emollients daily.
Exclusion Criteria
* A history of eczema herpeticum within 12 months, and/or a history of 2 or more episode of eczema herpeticum in the past.
* Participants who are currently experiencing a skin infection that requires treatment, or is currently being treated, with topical or systemic antibiotics.
* Have any serious illness that is anticipated to require the use of systemic corticosteroids or otherwise interfere with study participation or require active frequent monitoring (e.g., unstable chronic asthma).
* Have been treated with the following therapies:
* Monoclonal antibody for less than 5 half-lives prior to randomization.
* Received prior treatment with any oral Janus kinase (JAK) inhibitor.
* Received any parenteral corticosteroids administered by intramuscular or intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study.
* Have had an intra-articular corticosteroid injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization.
* Have high blood pressure characterized by a repeated systolic blood pressure \>160 millimeters of mercury (mm Hg) or diastolic blood pressure \>100 mm Hg.
* Have had major surgery within the past eight weeks or are planning major surgery during the study.
* Have experienced any of the following within 12 weeks of screening: venous thromboembolic event (VTE), myocardial infarction (MI), unstable ischemic heart disease, stroke, or New York Heart Association Stage III/IV heart failure.
* Have a history of recurrent (≥ 2) VTE or are considered at high risk of VTE as deemed by the investigator.
* Have a history or presence of cardiovascular, respiratory, hepatic, chronic liver disease gastrointestinal, endocrine, hematological, neurological, lymphoproliferative disease or neuropsychiatric disorders or any other serious and/or unstable illness.
* Have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection including herpes zoster, tuberculosis.
* Have specific laboratory abnormalities.
* Have received certain treatments that are contraindicated.
* Pregnant or breastfeeding.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Incyte Corporation
INDUSTRY
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kozni ambulance Kutna Hora, s.r.o.
Kutná Hora, Central Bohemia, Czechia
Clintrial, s.r.o.
Prague, Hl. M. Praha, Czechia
Fakultni nemocnice Kralovske Vinohrady
Prague, Hl. M. Praha, Czechia
Fakultni Nemocnice v Motole
Prague, Hl. M. Praha, Czechia
Nemocnice Na Bulovce
Prague, Hl. M. Praha, Czechia
Nemocnice Novy Jicin a.s.
Nový Jičín, Moravskoslezský kraj, Czechia
Fakultni Nemocnice Plzen
Plzen, Jizni Predmesti, Plzeň Region, Czechia
Fakultni Nemocnice U svate Anny
Brno, South Moravian, Czechia
Krajska zdravotni a.s. - Masarykova nemocnice v Usti nad Labem, o.z.
Ústí nad Labem, Ustecký Kraj, Czechia
Aarhus Universitehospital Marselisborg Centret
Aarhus, , Denmark
Hopital Saint-Louis
Paris, Cedex 10, France
CHU de Bordeaux Hopital Saint Andre
Bordeaux, , France
CHRU de Brest - Hôpital Morvan
Brest, , France
CHU Grenoble Alpes
Grenoble Cédex 9, , France
Chru De Nantes Hotel-Dieu
Nantes, , France
CHU de Nice Hopital de L'Archet
Nice, , France
Centre Hospitalier Lyon Sud
Pierre-Bénite, , France
Hopital Larrey
Toulouse, , France
Universitätsklinikum Freiburg
Freiburg im Breisgau, Baden-Wurttemberg, Germany
Klinikum der Universität München
München, Bavaria, Germany
Gemeinschaftspraxis Mahlow
Blankenfelde-Mahlow, Brandenburg, Germany
Rosenpark Research Geschäftsbereich der Rosenparkklinik GmbH
Darmstadt, Hesse, Germany
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
Frankfurt am Main, Hesse, Germany
Dermatologisches Zentrum Osnabrück Nord
Bramsche, Lower Saxony, Germany
Universitätsmedizin Göttingen
Göttingen, Lower Saxony, Germany
Universitätsmedizin Rostock
Rostock, Mecklenburg-Vorpommern, Germany
Universitätsklinikum Bonn
Bonn, North Rhine-Westphalia, Germany
Praxis Dr. Thomas Dirschka
Wuppertal, North Rhine-Westphalia, Germany
Praxis Gerlach
Dresden, Saxony, Germany
Universitätsklinikum Carl Gustav Carus
Dresden, Saxony, Germany
Universität Leipzig - Universitätsklinikum
Leipzig, Saxony, Germany
Universitätsklinikum Otto-von-Guericke-Universität
Magdeburg, Saxony-Anhalt, Germany
Hautarztzentrum Kiel
Kiel, Schleswig-Holstein, Germany
Universitätsklinikum Schleswig-Holstein
Kiel, Schleswig-Holstein, Germany
Universitätsklinikum Schleswig-Holstein
Lübeck, Schleswig-Holstein, Germany
Rothhaar Studien GmbH
Berlin, , Germany
ISA GmbH
Berlin, , Germany
Praxis für Ganzheitliche Dermatologie im Ärztehaus
Berlin, , Germany
TFS Trial Form Support GmbH
Hamburg, , Germany
King George Hospital
Vizag, Andhra Pradesh, India
Panchshil Hospital
Ahmedabad, Gujarat, India
Byramjee Jeejeebhoy Medical College & Civil Hospital
Ahmedabad, Gujarat, India
M S Ramaiah Medical College Hospital
Bangalore, Karnataka, India
Dr. D. Y. Patil Medical College & Hospital
Navi Mumbai, Maharashtra, India
Jehangir Hospital
Pune, Maharashtra, India
Seth GS Medical College & KEM Hospital
Mumbai, Maharshtra, India
All India Institue of Medical Sciences (AIIMS)
New Delhi, National Capital Territory of Delhi, India
Sir Ganga Ram Hospital
New Delhi, National Capital Territory of Delhi, India
Chennai Meenakshi Multispeciality Hospital
Chennai, Tamil Nadu, India
Gandhi Hospital
Secunderabad, Telangana, India
MV Hospital and Research Centre
Lucknow, Uttar Pradesh, India
Istituto Clinico Humanitas
Rozzano, Milano, Italy
Azienda Ospedaliera Universitaria Federico II
Napoli, , Italy
Azienda Ospedaliera - Universitaria Pisana
Pisa, , Italy
Policlinico di Tor Vergata
Roma, , Italy
Ospedale Policlinico Giambattista Rossi, Borgo Roma
Verona, , Italy
Kawashima Dermatology Clinic
Ichikawa-shi, Chiba, Japan
Fumimori Clinic
Fukuoka, Fukuoka, Japan
Hiroshima University Hospital
Hiroshima, Hiroshima, Japan
Queen's Square Dermatology and Allergology
Nishi-ku, Yokohama-city, Kanagawa, Japan
Yokohama City Minato Red Cross Hospital
Yokohama, Kanagawa, Japan
Kyoto Prefectural University of Medicine
Kyoto, Kyoto, Japan
Kume Clinic
Nishi-ku Sakai-shi, Osaka, Japan
Shimane University Hospital
Izumo, Shimane, Japan
JA Shizuoka Kohseiren Enshu Hospital
Hamamatsu, Shizuoka, Japan
Iidabashi Clinic
Chiyoda-ku, Tokyo, Japan
Nihonbashi Sakura Clinic
Chuo-ku, Tokyo, Japan
Sumire Dermatology Clinic
Edogawa-ku, Tokyo, Japan
NTT Medical Center Tokyo
Shinagawa-KU, Tokyo, Japan
Shirasaki Clinic
Takaoka-shi, Toyama, Japan
Yamanashi Prefectural Central Hospital
Kofu, Yamanashi, Japan
Fukuoka University Hospital
Fukuoka, , Japan
Grupo Médico CAMINO S.C.
Mexico City, Mexico City, Mexico
Hospital de Jesus I.A.P.
Mexico City, Mexico City, Mexico
Clínica Enfermedades Crónicas y Procedimientos Especiales SC
Morella, Michoacán, Mexico
CRI Centro Regiomontano de Investigacion S.C.
Monterrey, Nuevo León, Mexico
Hospital Univ. Dr. Jose Eleuterio Gonzalez
Monterrey, Nuevo León, Mexico
JM Research S.C.
Cuernavaca, , Mexico
RM Pharma Specialists S.A. de C.V.
Distrito Federal, , Mexico
Instituto de Investigaciones Aplicadas a la Neurociencia A.C
Durango, , Mexico
GBUZ Clinical dermatology and venereological dispensary
Krasnodar, , Russia
State scientific centre for dermatovenerology and cosmetolog
Moscow, , Russia
Russian state medical-stomatological university n.a. Evdokimov
Moscow, , Russia
SPb SBHI Skin-venerologic dispensary #10
Saint Petersburg, , Russia
LLC ArsVitae NorthWest
Saint Petersburg, , Russia
LLC Medical Center "Kurator"
Saint Petersburg, , Russia
Chang Gung Memorial Hospital - Kaohsiung
Kaohsiung City, , Taiwan
Taipei Medical University- Shuang Ho Hospital
New Taipei City, , Taiwan
Chung Shan Medical University Hospital
Taichung, , Taiwan
National Cheng Kung University Hospital
Tainan City, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Chang Gung Memorial Hospital - Taipei
Taipei, , Taiwan
Chang Gung Memorial Hospital - Linkou
Taoyuan, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Katoh N, Takita Y, Isaka Y, Nishikawa A, Torisu-Itakura H, Saeki H. Pooled Safety Analysis of Baricitinib in Adult Participants with Atopic Dermatitis in the Japanese Subpopulation from Six Randomized Clinical Trials. Dermatol Ther (Heidelb). 2022 Dec;12(12):2765-2779. doi: 10.1007/s13555-022-00828-5. Epub 2022 Oct 18.
Silverberg JI, DeLozier A, Sun L, Thyssen JP, Kim B, Yosipovitch G, Nunes FP, Gugiu PC, Doll HA, Eichenfield LF. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis. Health Qual Life Outcomes. 2021 Oct 23;19(1):247. doi: 10.1186/s12955-021-01877-8.
Thyssen JP, Buhl T, Fernandez-Penas P, Kabashima K, Chen S, Lu N, DeLozier AM, Casillas M, Stander S. Baricitinib Rapidly Improves Skin Pain Resulting in Improved Quality of Life for Patients with Atopic Dermatitis: Analyses from BREEZE-AD1, 2, and 7. Dermatol Ther (Heidelb). 2021 Oct;11(5):1599-1611. doi: 10.1007/s13555-021-00577-x. Epub 2021 Jul 18.
King B, Maari C, Lain E, Silverberg JI, Issa M, Holzwarth K, Brinker D, Cardillo T, Nunes FP, Simpson EL. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials. Am J Clin Dermatol. 2021 May;22(3):395-405. doi: 10.1007/s40257-021-00602-x. Epub 2021 Apr 7.
Reich K, DeLozier AM, Nunes FP, Thyssen JP, Eichenfield LF, Wollenberg A, Ross Terres JA, Watts SD, Chen YF, Simpson EL, Silverberg JI. Baricitinib improves symptoms in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: patient-reported outcomes from two randomized monotherapy phase III trials. J Dermatolog Treat. 2022 May;33(3):1521-1530. doi: 10.1080/09546634.2020.1839008. Epub 2020 Nov 22.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
A Study of Baricitinib (LY3009104) in Adults With Moderate to Severe Atopic Dermatitis (Eczema) (BREEZE-AD1)
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I4V-MC-JAHL
Identifier Type: OTHER
Identifier Source: secondary_id
2017-000870-12
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
16580
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.